文献速递临床试验与 GCP基础与转化研究

干扰素β-1a治疗COVID-19患者的随机对照试验方案(INTERCOP)

Interferon β-1a (IFNβ-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-11-23

主要结局为鼻咽拭子SARS-CoV-2转阴时间。

要点

  • 轻中度COVID-19患者标准治疗加用IFNβ-1a 44 mcg皮下注射,每周三次,共2周。
  • 主要结局为鼻咽拭子SARS-CoV-2转阴时间,次要结局包括7分序贯量表临床严重度变化等。
  • 两组均不使用其他抗病毒药物,探索性结局包括干扰素刺激基因mRNA表达和抗体等。

核心结论

  • INTERCOP是首个专门评估IFNβ-1a对COVID-19患者临床获益的研究。
  • 若主要结局达标且治疗安全,IFNβ-1a或可用于降低轻中度患者传染性。
  • 若IFNβ-1a缩短住院时间或改善临床状态,可能成为COVID-19治疗的基石。

研究设计与样本

  • 随机、对照、开放标签、单中心II期试验(INTERCOP)。
  • 按2:1随机分配至IFNβ-1a联合标准治疗组或单纯标准治疗组。
  • 两组均不使用其他抗病毒药物作为方案组成部分。

关键数值与推荐

  • 主要结局:鼻咽拭子SARS-CoV-2转阴时间。
  • 次要结局包括7分序贯量表临床严重度改善或恶化(含转入ICU和死亡)、无氧疗和无呼吸机天数、死亡率。
  • 次要结局还包括肺部CT严重度评分变化、住院时长、鼻咽拭子病毒载量下降、严重不良事件数、器官功能障碍生化标志物变化。
  • 探索性结局包括血细胞计数、细胞因子和炎症谱、外周血干扰素刺激基因mRNA表达谱、SARS-CoV-2及IFNβ-1a抗体。
  • 试验注册号:EudraCT 2020-002458-25(2020年5月11日注册);ClinicalTrials.gov NCT04449380。

临床怎么用

  • 对鼻拭子SARS-CoV-2阳性、有肺炎影像学征象的轻中度COVID-19患者,可考虑在标准治疗基础上加用IFNβ-1a 44 mcg皮下注射每周三次共2周。
  • 治疗期间需监测鼻咽拭子转阴时间、7分序贯量表临床严重度、氧疗和呼吸机使用天数及严重不良事件。

局限性

  • 本研究为单中心、开放标签设计。
  • 原文未报告样本量计算依据、主要结局预期效应量及统计假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pharmacological therapies of proven efficacy in coronavirus disease 2019 (COVID-19) are still lacking. We have identified IFNβ-1a as the most promising drug to be repurposed for COVID-19. The rationale relies on the evidence of IFNβ anti-viral activity in vitro against SARS-CoV-2 and animal models resembling SARS-CoV-2 infection and on a recent clinical trial where IFNβ was indicated as the key component of a successful therapeutic combination. METHODS: This is a randomized, controlled, open-label, monocentric, phase II trial (INTERCOP trial). One hundred twenty-six patients with positive swab detection of SARS-CoV-2, radiological signs of pneumonia, and mild-to-moderate disease will be randomized 2:1 to IFNβ-1a in addition to standard of care vs standard of care alone. No other anti-viral drugs will be used as part of the regimens, both in the control and the intervention arms. IFNβ-1a will be administered subcutaneously at the dose of 44 mcg (equivalent to 12 million international units) three times per week, at least 48 h apart, for a total of 2 weeks. The primary outcome is the time to negative conversion of SARS-CoV-2 nasopharyngeal swabs. Secondary outcomes include improvement or worsening in a clinical severity score measured on a 7-point ordinal scale (including transfer to intensive care unit and death), oxygen- and ventilator-free days, mortality, changes in pulmonary computed tomography severity score, hospital stay duration, reduction of viral load measured on nasopharyngeal swabs, number of serious adverse events, and changes in biochemical markers of organ dysfunction. Exploratory outcomes include blood cell counts, cytokine and inflammatory profile, peripheral mRNA expression profiles of interferon-stimulated genes, and antibodies to SARS-CoV-2 and to IFNβ-1a. INTERCOP is the first study to specifically investigate the clinical benefits of IFNβ-1a in COVID-19 patients. DISCUSSION: Potential implications of this trial are multifaceted: should the primary outcome be fulfilled and the treatment be safe, one may envisage that IFNβ-1a be used to reduce the infectivity of patients with mild-to moderate disease. In case IFNβ-1a reduced the duration of hospital stay and/or ameliorated the clinical status, it may become a cornerstone of COVID-19 treatment. TRIAL REGISTRATION: EudraCT 2020-002458-25. Registered on May 11, 2020 ClinicalTrials.gov Identifier: NCT04449380.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bosi E, Bosi C, Rovere Querini P, et al. Interferon β-1a (IFNβ-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial. Trials. 2020. PMID: 33225960. doi:10.1186/s13063-020-04864-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。